{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Activated+Prothrombin+Complex+Concentrate",
    "query": {
      "intervention": "Activated Prothrombin Complex Concentrate"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Activated+Prothrombin+Complex+Concentrate&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T20:22:21.182Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01757405",
      "title": "Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIIa BI (rFVIIa BI)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2013-02-20",
      "completion_date": "2014-11-11",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01757405"
    },
    {
      "nct_id": "NCT04567511",
      "title": "Hemlibra in Mild Hemophilia A",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Factor VIII Deficiency, Congenital"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana Hemophilia &Thrombosis Center, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "5 Years to 45 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2022-07-25",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04567511"
    },
    {
      "nct_id": "NCT05156983",
      "title": "A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coagulation Disorder"
      ],
      "interventions": [
        {
          "name": "TAK-330",
          "type": "DRUG"
        },
        {
          "name": "SOC 4F-PCC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 440,
      "start_date": "2022-08-24",
      "completion_date": "2028-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 13,
      "location_summary": "Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more",
      "locations": [
        {
          "city": "Arkansas City",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05156983"
    },
    {
      "nct_id": "NCT03809481",
      "title": "Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heparin-induced Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Danaparoid Sodium",
          "type": "DRUG"
        },
        {
          "name": "Argatroban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aspen Global Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "2 Weeks to 100 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-05-16",
      "completion_date": "2022-06-10",
      "has_results": false,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Minneapolis, Minnesota • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03809481"
    },
    {
      "nct_id": "NCT05010707",
      "title": "Transgender Estradiol Affirming Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transgenderism"
      ],
      "interventions": [
        {
          "name": "Transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Pro-thrombotic markers",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Metabolic markers",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Hormone Profile",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Daily Sublingual Tablet",
          "type": "DRUG"
        },
        {
          "name": "BID Sublingual Tablet",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "MALE",
        "summary": "18 Years to 30 Years · Male only"
      },
      "enrollment_count": 39,
      "start_date": "2021-08-02",
      "completion_date": "2024-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05010707"
    },
    {
      "nct_id": "NCT06883240",
      "title": "An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrand Disease, Type 3"
      ],
      "interventions": [
        {
          "name": "Von Willebrand Factor Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Von Willebrand Factor Concentrates and Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Factor VIII Concentrates",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Activated Factor VII",
          "type": "DRUG"
        },
        {
          "name": "Activated Prothrombin Complex Concentrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2025-04-29",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883240"
    },
    {
      "nct_id": "NCT05281718",
      "title": "Factor IX as Adjunctive Therapy to Emicizumab (EMIX)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Factor IX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tulane University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "12 Years to 120 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-01",
      "completion_date": "2024-07-14",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 2,
      "location_summary": "Metairie, Louisiana • New Orleans, Louisiana",
      "locations": [
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281718"
    },
    {
      "nct_id": "NCT02557672",
      "title": "PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bleeding",
        "Blood Loss, Surgical",
        "Cardiovascular Surgical Procedures",
        "Prothrombin Complex Concentrates",
        "Fresh Frozen Plasma"
      ],
      "interventions": [
        {
          "name": "Prothrombin complex concentrate (Human)",
          "type": "DRUG"
        },
        {
          "name": "Fresh frozen plasma (FFP)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2016-08",
      "completion_date": "2022-01",
      "has_results": true,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02557672"
    },
    {
      "nct_id": "NCT03921294",
      "title": "HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Haemophilic Pseudotumour"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana Hemophilia &Thrombosis Center, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2019-05-15",
      "completion_date": "2022-03-16",
      "has_results": true,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03921294"
    },
    {
      "nct_id": "NCT04563520",
      "title": "SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        },
        {
          "name": "FEIBA",
          "type": "DRUG"
        },
        {
          "name": "rFVIIa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2026-09",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-05T20:22:21.182Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563520"
    }
  ]
}